Induced pluripotent stem cells (iPSC) derived from somatic cells of patients hold great promise for autologous cell therapies. Saito and colleagues generated iPSCs from T-cell receptor transgenic T cells, and established a syngeneic preclinical mouse model of evaluating therapeutic efficacy of iPSC-derived T cells. The image depicts immunofluorescence staining of iPSCs for a pluripotency marker, SSEA1 (green), and DAPI (blue). The study found that iPSC-derived T cells exhibit potent antitumor reactivity in vitro and in vivo. For details, see article by Saito and colleagues on page 3473.